Pdf Ruthenium Brachytherapy For Intraocular Growth Of A Conjunctival The aim of this study is to report the use of ruthenium brachytherapy as an adjunctive treatment in the management of an intraocular extension of the conjunctival squamous cell carcinoma (scc). Uveal melanoma is the most common primary intraocular malignancy. the aim of this retrospective study was to report the results after ruthenium 106 (ru 106) plaque brachytherapy for uveal melanoma in terms of tumor control, visual acuity, radiation related complications, tumor recurrence, metastases, and patients’ survival rate during 4 years’ follow up.
Pdf Outcome Analysis Of Visual Acuity And Side Effect After Ruthenium The aim of this study is to report the use of ruthenium brachytherapy as an adjunctive treatment in the management of an intraocular extension of the conjunctival squamous cell carcinoma (scc). in 2013, a 73 year old man presented with a tumor blocking the angle and infiltrating corneal endothelium. The aim of this study is to report the use of ruthenium brachytherapy as an adjunctive treatment in the management of an intraocular extension of the conjunctival squamous cell carcinoma (scc). in 2013, a 73 year old man presented with a tumor blocking the angle and infiltrating corneal endothelium. …. Localised ocular argyrosis. iatrogenic ocular argyrosis should be considered in the differential diagnosis of new pigmented lesions in patients treated with ru 106 brachytherapy. this study is the first to unequivocally identify the cause of some post brachytherapy ocular surface pigmentation as caused by silver. The aim of this study is to report the use of ruthenium brachytherapy as an adjunctive treatment in the management of an intraocular extension of the conjunctival squamous cell carcinoma (scc).
Comments are closed.